Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Boya IVIG in Primary Immune Deficiency
NCT06150833Phase 3Not yet recruiting
- Sponsor
- Azidus Laboratories Limited
- Start
- Sep 2026
- Primary completion
- Sep 2028
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, open-label, single-arm trial of intravenous immunoglobulin G in primary immunodeficiency (PI), sponsored by Azidus Laboratories Limited. Primary endpoint: Mean number of serious bacterial infections at 56 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
intravenous immunoglobulin G
03
Conditions
primary immunodeficiency (PI)
Beyond the preview
Go deeper on NCT06150833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06150833.